Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q 2025Expect to ...
Thank you, operator, and thank you all for joining us on today's call to discuss Penumbra's earnings release for 2025. During ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback